Colorectal Oncology Research Review, Issue 22

In this issue:

Rectal cancer
• Poor compliance to adjuvant chemotherapy
• …and survival dependent on patient factors
• Longer delay to surgery does not improve pCR
Colon cancer
• Adjuvant chemotherapy improves OS in
stage II colon cancer
• Improved compliance to shorter treatment
Metastatic colorectal cancer
• Panitumumab non-inferior to cetuximab
• Bevacizumab continuation not cost-effective
• Survival not improved with FOLFOX6 +
icrucumab or ramucirumab
• ... or addition of PI3K inhibitor to cetuximab
• Personalisation of 5FU dosing using
therapeutic drug management

Please login below to download this issue (PDF)

Subscribe